



(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 31/712 (2006.01)
A61K 38/04 (2006.01)

(21) International Application Number:

PCT/US2024/034923

(22) International Filing Date:

21 June 2024 (21.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/509,696 22 June 2023 (22.06.2023) US

(71) Applicant: **DENALI THERAPEUTICS INC.** [US/US];
161 Oyster Point Boulevard, South San Francisco, California 94080 (US).

(72) Inventors: **BARKER, Scarlett**; c/o Denali Therapeutics Inc., 161 Oyster Point Boulevard, South San Francisco, California 94080 (US). **DEVOS, Sarah L.**; c/o Denali Therapeutics Inc., 161 Oyster Point Boulevard, South San Francisco, California 94080 (US). **THAYER, Mai B.**; c/o Denali Therapeutics Inc., 161 Oyster Point Boulevard, South San Francisco, California 94080 (US). **KLAR, Richard**; c/o Denali Therapeutics Inc., 161 Oyster Point Boulevard, South San Francisco, California 94080 (US).

MICHEL, Sven; c/o Denali Therapeutics Inc., 161 Oyster Point Boulevard, South San Francisco, California 94080 (US). **JASCHINSKI, Frank**; c/o Denali Therapeutics Inc., 161 Oyster Point Boulevard, South San Francisco, California 94080 (US). **ROTHKIRCH, Larissa**; c/o Denali Therapeutics Inc., 161 Oyster Point Boulevard, South San Francisco, California 94080 (US).

(74) Agent: **EKENA, Kirk et al.**; Alston & Bird LLP, Vantage South End, 1120 South Tryon Street, Suite 300, Charlotte, North Carolina 28203-6818 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION




FIG. 1

(57) Abstract: Provided herein are MAPT antisense oligonucleotides that are capable of modulating the expression of a MAPT target nucleic acid. Also provided herein are methods of use thereof.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

15 May 2025 (15.05.2025)